Recent Updates
Recently added Catalysts
HCM Neutral Sentiment Score: 60/100

Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Monday, March 16 , 202 5 : HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance

Key Takeaway: HUTCHMED (China) Limited announced the vesting of non-performance based awards under its Long Term Incentive Plan for Dr. Weiguo Su, the Executive Director, CEO, and Chief Scientific Officer. The awards, granted on March 13, 2024, were vested on March 13, 2026. This notification fulfills the requirements of the UK Market Abuse Regulation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Weiguo Su received a significant number of shares, indicating confidence in leadership.
  • The vesting of awards reflects positive growth and recognition in the company.
  • The announcement adheres to UK Market Abuse Regulation, indicating transparency.

Full Press Release Details

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ - Monday, March 16, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan ("LTIP") on March 13, 2024 to the following person discharging managerial responsibilities were vested on March 13, 2026:-
Award Holder Number of ordinary shares
Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer) 19,913
The notification set out below is provided in accordance with the requirements of the UK Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Weiguo Su
2 Reason for the notification
a) Position/status Executive Director, Chief Executive Officer and Chief Scientific Officer
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Identification code Ordinary Shares of US$0.10 Ordinary Share with DI ISIN: KYG4672N1016
b) Nature of the transaction Vesting of awards granted on March 13, 2024 under HUTCHMED's LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 19,913 ordinary shares
d) Aggregated information - Aggregated volume - Price N/A
e) Date of the transaction 2026-03-13
f) Place of the transaction Outside a trading venue
Investor Enquiries +852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting - +44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick - Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500
Deutsche Numis Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith +44 20 7260 1000

Frequently Asked Questions

What is the Long Term Incentive Plan at HUTCHMED?

The Long Term Incentive Plan (LTIP) grants awards to managerial personnel.

Who received awards under the LTIP on March 13, 2024?

Dr. Weiguo Su received 19,913 ordinary shares under the LTIP.

When did the awards under the LTIP vest?

The awards vested on March 13, 2026.

What is Dr. Weiguo Su's position at HUTCHMED?

He is the Executive Director, CEO, and Chief Scientific Officer.

How many shares were vested for Dr. Su?

A total of 19,913 ordinary shares were vested.

Last updated: Mar 16, 2026